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The classical survival curves produced by Puck and Marcus1 50 years ago, demonstratingdecreasing clonogenic survival with increasing doses of radiation, have become a corner-
stone of modern clinical radiobiology, underpinning the notion that for epithelial cancers,
escalating the radiotherapy dose increases the probability of local cure, and that the only
obstacle to achieving this is the tolerance of the incidentally irradiated adjacent normal tissues.
In the case of non-small cell lung cancer (NSCLC), the evidence for a dose-response
relationship is provided by the Radiation Therapy Oncology Group’s landmark trial 73-01,
which demonstrated superior response rates in patients randomized to a dose of 60 Gy
compared with lower doses.2 This did not, however, translate into longer survival, and
there is only limited evidence suggesting a dose-survival relationship up to 60 Gy,
including our own non-randomized experience.3 Nevertheless, 60 Gy, conventionally
fractionated, is generally safe and has become a universal standard of care for inoperable
NSCLC.
Recent advances in radiation therapy technology, such as three-dimensional (3D)
treatment planning, respiratory gating, intensity-modulated radiotherapy, and F18-deoxy-
glucose positron emission tomography-assisted tumor volume definition, all of which
allow the creation of a radiation dose envelope that conforms more closely to the shape
of the cancer, have opened up opportunities for reducing the dose to the surrounding
healthy tissues, theoretically allowing dose escalation beyond 60 Gy while not exceeding
those dose constraints traditionally applied to organs at risk.
In this issue of the journal, Urbanic et al. report the use of 3D techniques to deliver
a dose of 80.5 Gy in a cohort of patients with early-stage NSCLC. So as not to unduly
prolong overall treatment time, a potential cause of treatment failure, the radiotherapy was
delivered as 2.3-Gy fractions. The volume of normal tissue irradiated was further limited
by not electively irradiating mediastinal lymph nodes. Although many of the patients had
severe co-morbidities that typically represent competing risks for death in a population of
this kind, the major cause of death was still NSCLC, and local progression was the
dominant cause of failure. Why are these results so disappointing? There is always a
danger that, in minimizing the dose to the surrounding tissues, the margins on the tumor
become too tight, and there is the potential for geographic miss, particularly if allowance
is not made for internal organ motion resulting from the cardiac and respiratory cycles, as
seemed to be the case in this study.
Urbanic et al. have nevertheless demonstrated the feasibility of delivering doses well
in excess of the 60-Gy benchmark, thereby confirming other reports that dose escalation
using 3D techniques is not associated with excessive short- or medium-term toxicity.4–6
Unfortunately, none of these studies was randomized, and interpretation of the outcomes
is further complicated by the requirement that dose escalation to the highest levels is
Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.
Address correspondence to: David Ball, MB, BS, MD, FRANZCR, Chair, Lung Service, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett St,
Melbourne, Victoria, 8006, Australia.
Copyright © 2006 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/06/0102-0107
Journal of Thoracic Oncology • Volume 1, Number 2, February 2006 107
usually only possible with the smallest tumors, which may
have an inherently better prognosis. Although researchers at
the University of Michigan4 and Memorial SloanKettering5
have recently reported an apparent improvement in survival
associated with dose escalation, this was not the experience
of the Radiation Therapy Oncology Group.6
We should also not forget that superior outcomes can
sometimes be achieved with lower doses of radiotherapy by
shortening overall treatment time in the case of continuous
hyperfractionated accelerated radiotherapy7 or in the case of
esophageal cancer, for example, by the addition of concom-
itant chemotherapy.8
Investigators designing radiotherapy studies for
NSCLC are currently spoiled for choice in regard to prom-
ising new strategies that include, in addition to dose escala-
tion, shortening overall treatment time and the concomitant
administration of new chemotherapeutic and biological
agents. To evaluate the contribution each of these might make
individually or in combination to reduce the depressingly
high rate of local failure in patients irradiated for NSCLC will
be a challenge requiring carefully designed and conducted
randomized trials. The fact that we can dose escalate is not
sufficient evidence that it works.
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